Piramal Pharma swung to a Rs 136 crore Q3 loss as revenue fell 3%, hit by CDMO destocking, weak US biopharma funding, trade uncertainty and...

Indian stocks show promise as valuations cool and earnings improve. Anshul Saigal of Saigal Capital sees selective opportunities for long-t...

Brokerage firms remain bullish on Navin Fluorine, PTC Industries, and Eternal, citing strong execution, capacity expansion, and long-term g...

Trust MF's CIO, Mihir Vora, favors healthcare investments in R&D, CDMO, diagnostics, and hospitals, while being cautious about generic US p...

Indian equity markets showed gains despite geopolitical tensions. Regulator confidence, GDP growth, and RBI support boosted the market. Sub...

So, it is again going to be back ended in terms of how the growth picture looks like because FY25 is a given is a soft year in terms of bot...

Tata Consumer is a very different business compared to where it was even till last year and very-very different from where it was four or f...

I think silver lining in terms of earnings growth will be coming in from the export related sectors. The ITs, the pharmas, banks, in any ca...

The Indian stock market is expected to remain in the range of 23,000 to 25,000 for the next three months. A breakout may occur with better ...

CIO Rajesh Bhatia of ITI MF sees largecap valuations as reasonable, favoring private banks for their solid business models and predictabili...

Markets had crossed all-time highs last month and despite the recent correction valuations are not cheap, trading at premiums to historic a...

Chakri Lokapriya talks about the current challenges in metals due to China's weak recovery and the positive outlook for Indian IT firms. He...

Piramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...

The funding to keep his drug discovery pursuits alive may not be a problem, as Jasti in December last year sold his profitable contract dev...

Rise in headwinds in the pharma industry due to inflation, increase in raw material costs, and excessive competition led to price erosion i...

P&G Hygiene and Health Care reported a 29.2 per cent decline in its net profit at Rs 48.98 crore for the quarter ended June 2021. The compa...

Jubilant Life Sciences is a midcap company, operating in pharmaceuticals and health care sector.